Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) EPS (Basic) : $-0.08 (TTM As of Jan. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals EPS (Basic)?

Cotinga Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Jan. 2020 was $-0.02. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jan. 2020 was $-0.08.

Cotinga Pharmaceuticals's EPS (Diluted) for the three months ended in Jan. 2020 was $-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2020 was $-0.08.

Cotinga Pharmaceuticals's EPS without NRI for the three months ended in Jan. 2020 was $-0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jan. 2020 was -0.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cotinga Pharmaceuticals EPS (Basic) Historical Data

The historical data trend for Cotinga Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals EPS (Basic) Chart

Cotinga Pharmaceuticals Annual Data

Trend

Apr10

Apr11

Apr12

Apr13

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

EPS (Basic)

Get a 7-Day Free Trial

-0.32

-0.30

-0.31

-0.24

-0.09

Cotinga Pharmaceuticals Quarterly Data
	Apr15	Jul15	Oct15	Jan16	Apr16	Jul16	Oct16	Jan17	Apr17	Jul17	Oct17	Jan18	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20
EPS (Basic)	Get a 7-Day Free Trial															-0.01	-0.03	-0.02	-0.02	-0.02

Cotinga Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cotinga Pharmaceuticals's Basic EPS for the fiscal year that ended in Apr. 2019 is calculated as

Basic EPS (A: Apr. 2019 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.016	-	0)	/	21.957
	=	-0.09

Cotinga Pharmaceuticals's Basic EPS for the quarter that ended in Jan. 2020 is calculated as

Basic EPS (Q: Jan. 2020 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.408	-	0)	/	21.986
	=	-0.02

EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08

Cotinga Pharmaceuticals (OTCPK:COTQF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cotinga Pharmaceuticals EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1

Website

http://www.cotingapharma.com

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results

By GlobeNewswire GlobeNewswire • 04-03-2018

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire • 05-22-2019